ORLANDO, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, today announced the appointment of Joel Kanter to the Company’s Board of Directors as an Independent Director.
Austin Lewis, MEDITE’s Chairman stated, “We are honored to have attracted someone of Joel’s caliber to MEDITE’s Board of Directors and look forward to his contributions during this exciting time in our Company history. Joel has an exceptional track record of impacting change and positive results in both social and corporate endeavors, helping small businesses to grow into larger successful companies as both a financier, as well as an advisor within the healthcare industry. We believe he will be a tremendous asset to MEDITE’s Board moving forward.”
Mr. Kanter commented, “I am excited to join MEDITE’s Board of Directors and to work with the Company to capitalize on the commercial opportunities that lie ahead. The Company is well positioned to expand its commercial portfolio to include innovative products in emerging growth areas such as cytology, and ultimately, personalized medicine, as well as broadening its geographic footprint worldwide. I look forward to supporting this dedicated management team to execute on its growth strategy.”
Mr. Kanter has more than 30 years of experience in the financial services industry, providing financing to businesses ranging from start-ups and early stage development companies, to larger and more mature enterprises. Mr. Kanter has served as President of Windy City, Inc., a privately held investment firm, since 1986, and previously served as the President, and subsequently as the President and Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company, until its sale to Tower Hill Capital Group in 1999 in a transaction valued at approximately $400 million. Previous experience also includes service as a Legislative Assistant to former Congressman Abner J. Mikva, Special Assistant to the National Association of Attorneys General and Staff Director of the House Rules Committee's Subcommittee on Legislative Process Chaired by the late Congressman Gillis W. Long.
Mr. Kanter also brings a wealth of expertise through serving on the Board of Directors of several medical device companies, including one other public company, MagnaLabs, Inc., formerly involved in the development of a cardiac MRI device. Mr. Kanter also serves on the Boards of several private concerns including Fibralign Corporation, Mercator MedSystems, Inc., Orpheus Biosciences, Inc., and Serpin Pharma.
Mr. Kanter is replacing David E. Patterson on the Company’s Board of Directors, effective immediately.
About MEDITE Cancer Diagnostics, Inc.
MEDITE Cancer Diagnostics, Inc. is a global company that specializes in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases. The Company is developing a suite of innovative products, both Histo-Pathology (tissue biopsy) and Cyto-Pathology (liquid cell) based, that target large markets and cover the complete laboratory process from biopsy to finished slide, and through diagnosis. MEDITE’s current and future products assist in the early diagnoses of cancer, with a target result of contributing to more lives saved at lower costs. MEDITE’s products are currently being distributed in over 80 countries worldwide.
Forward Looking Statement
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding future operating performance, events, trends and plans. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding our future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expects,” “intends,” “plans,” “projects,” “estimates,” “anticipates,” or “believes” or the negative thereof or any variation thereon or similar terminology or expressions. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause our actual results to differ from our expectations include, but are not limited to, MEDITE’s ability to maintain and grow its revenues. Readers are cautioned not to place undue reliance on our forward-looking statements, as they speak only as of the date made. Such statements are not guarantees of future performance or events and we undertake no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances occurring after the date hereof.
Steve Silver / Valter Pinto
KCSA Strategic Communications
Phone: 212-896-1220 / 212-896-1254
Source:MEDITE Cancer Diagnostics, Inc.